Łucja Ilkiewicz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Łucja Ilkiewicz has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Kalisz
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
6 shared publications - Aleksandra Kinga Łysak
Provincial Integrated Hospital, ul. Grunwaldzka 45, 25-736 Kielce, Poland
3 shared publications - Damian GręBosz
Faculty of Medicine, Jan Kochanowski University in Kielce, al. IX Wieków Kielc 19a, 25-516 Kielce, Poland
3 shared publications - Jakub Gałwiaczek
Provincial Integrated Hospital, ul. Grunwaldzka 45, 25-736 Kielce, Poland
3 shared publications - Jakub Janczura
Faculty of Medicine, Jan Kochanowski University, Kielce, Poland
3 shared publications - Jarosław Dudek
St. Raphael’s Voivodeship Specialist Hospital in Czerwona Góra, ul. Czerwona Góra 10, 26-060 Chęciny, Poland
3 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 72, 75609
Effects of Fixture Congestion on Post-Match Recovery Kinetics in Soccer Players: A Narrative Review
Background. Fixture congestion is common in soccer and reduces the time available for recovery between matches. Recovery is multidimensional, and physical, neuromuscular, biochemical, and perceptual markers may normalize at different rates. Aim. This narrative review aimed to synthesize evidence on the effects of fixture congestion on post-match recovery kinetics in soccer players. Material and methods. A predefined full-text literature set relevant to fixture congestion, fatigue, post-match recovery, workload, performance, and injury risk was synthesized qualitatively. Original studies formed the primary evidence base, with review articles used for context. Results. Recovery was heterogeneous. Several neuromuscular, muscular, biochemical, and perceptual variables remained altered at 48 h, while selected performance measures recovered by 72 h. Congested schedules and high match exposure were associated with slower recovery of selected outcomes even when performance was preserved. Conclusions. A return of physical performance does not necessarily indicate complete recovery. Fixed 48- or 72-h intervals should not be interpreted alone as evidence of full restoration. Monitoring should integrate individual match exposure, workload, performance, and perceptual responses.
- 16 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 72, 75609
Open AccessEffects of Fixture Congestion on Post-Match Recovery Kinetics in Soccer Players: A Narrative Review
Background. Fixture congestion is common in soccer and reduces the time available for recovery between matches. Recovery is multidimensional, and physical, neuromuscular, biochemical, and perceptual markers may normalize at different rates. Aim. This narrative review aimed to synthesize evidence on the effects of fixture congestion on post-match recovery kinetics in soccer players. Material and methods. A predefined full-text literature set relevant to fixture congestion, fatigue, post-match recovery, workload, performance, and injury risk was synthesized qualitatively. Original studies formed the primary evidence base, with review articles used for context. Results. Recovery was heterogeneous. Several neuromuscular, muscular, biochemical, and perceptual variables remained altered at 48 h, while selected performance measures recovered by 72 h. Congested schedules and high match exposure were associated with slower recovery of selected outcomes even when performance was preserved. Conclusions. A return of physical performance does not necessarily indicate complete recovery. Fixed 48- or 72-h intervals should not be interpreted alone as evidence of full restoration. Monitoring should integrate individual match exposure, workload, performance, and perceptual responses.
- Open Access
- 15 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 73, 75538
Exercise-Associated Hyponatremia in Endurance Sports: Risk Factors, Pathophysiology and Prevention – A Narrative Review
Background. Exercise-associated hyponatremia (EAH) is a potentially serious disturbance of water and sodium homeostasis occurring during or after prolonged endurance exercise. Although excessive fluid intake is an established risk factor, EAH results from interactions between fluid intake, arginine vasopressin activity, sodium balance, exercise duration, environmental conditions, and individual characteristics. Aim. This narrative review aimed to summarize current evidence on the epidemiology, pathophysiology, risk factors, and prevention of EAH in endurance sports, with emphasis on recent findings and modifiable factors. Methods. Relevant literature was identified primarily through PubMed searches and reference-list screening. Particular emphasis was placed on studies published between 2020 and 2026, while selected earlier studies were retained as foundational evidence. Original studies, systematic and narrative reviews, clinical guidelines, and relevant physiological research were considered. Results. EAH occurs in marathon running, triathlon, ultramarathon, and mountain endurance events, with substantial variation in reported prevalence. Excessive fluid intake relative to free-water excretion remains the most consistently identified modifiable risk factor. However, EAH may also occur despite body mass loss, indicating that sodium losses and other physiological mechanisms contribute in some athletes. Exercise-associated arginine vasopressin activity facilitates water retention during prolonged exercise. Current evidence does not support universal sodium supplementation as a reliable preventive strategy. Hydration beliefs and planned drinking behaviors may also influence risk. Conclusions. EAH is a multifactorial disorder rather than simply a consequence of sodium depletion or excessive water consumption. Prevention should emphasize avoiding forced drinking, individualized hydration strategies, and athlete education regarding fluid and sodium balance.
- 15 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 73, 75538
Open AccessExercise-Associated Hyponatremia in Endurance Sports: Risk Factors, Pathophysiology and Prevention – A Narrative Review
Background. Exercise-associated hyponatremia (EAH) is a potentially serious disturbance of water and sodium homeostasis occurring during or after prolonged endurance exercise. Although excessive fluid intake is an established risk factor, EAH results from interactions between fluid intake, arginine vasopressin activity, sodium balance, exercise duration, environmental conditions, and individual characteristics. Aim. This narrative review aimed to summarize current evidence on the epidemiology, pathophysiology, risk factors, and prevention of EAH in endurance sports, with emphasis on recent findings and modifiable factors. Methods. Relevant literature was identified primarily through PubMed searches and reference-list screening. Particular emphasis was placed on studies published between 2020 and 2026, while selected earlier studies were retained as foundational evidence. Original studies, systematic and narrative reviews, clinical guidelines, and relevant physiological research were considered. Results. EAH occurs in marathon running, triathlon, ultramarathon, and mountain endurance events, with substantial variation in reported prevalence. Excessive fluid intake relative to free-water excretion remains the most consistently identified modifiable risk factor. However, EAH may also occur despite body mass loss, indicating that sodium losses and other physiological mechanisms contribute in some athletes. Exercise-associated arginine vasopressin activity facilitates water retention during prolonged exercise. Current evidence does not support universal sodium supplementation as a reliable preventive strategy. Hydration beliefs and planned drinking behaviors may also influence risk. Conclusions. EAH is a multifactorial disorder rather than simply a consequence of sodium depletion or excessive water consumption. Prevention should emphasize avoiding forced drinking, individualized hydration strategies, and athlete education regarding fluid and sodium balance.
- Open Access
- 14 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 73, 75617
Sudden Cardiac Death in Athletes: Risk Factors, Screening and Prevention
Background: Sudden cardiac death (SCD) in athletes is rare, but it remains an important problem because it may occur unexpectedly in individuals with no previously recognized cardiovascular disease. Its causes differ with age and include cardiomyopathies, coronary artery abnormalities, myocarditis, coronary artery disease and primary electrical disorders. Aim: To summarize current evidence on the epidemiology, causes, risk factors and warning signs of SCD in athletes, and to discuss cardiovascular screening, prevention, emergency management and return to sport. Materials and methods: A narrative review was conducted using PubMed, Web of Science and Google Scholar. English-language full-text studies published between 2015 and 2026 were considered, including original studies, systematic reviews, meta-analyses and narrative reviews. Results: SCD is uncommon, but its incidence varies between athlete populations and is higher in males. In younger athletes, cardiomyopathies, coronary artery anomalies and primary electrical disorders are important causes, while coronary artery disease becomes more relevant with age. ECG screening may improve the detection of cardiovascular conditions associated with SCD, although its effect on mortality remains uncertain. Early CPR and rapid AED use are consistently associated with better survival after sports-related cardiac arrest. Conclusions: Prevention should combine cardiovascular assessment with awareness of warning symptoms and effective emergency preparedness. Return-to-sport decisions should be individualized according to the underlying cardiovascular condition and follow-up findings.
- 14 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 73, 75617
Open AccessSudden Cardiac Death in Athletes: Risk Factors, Screening and Prevention
Background: Sudden cardiac death (SCD) in athletes is rare, but it remains an important problem because it may occur unexpectedly in individuals with no previously recognized cardiovascular disease. Its causes differ with age and include cardiomyopathies, coronary artery abnormalities, myocarditis, coronary artery disease and primary electrical disorders. Aim: To summarize current evidence on the epidemiology, causes, risk factors and warning signs of SCD in athletes, and to discuss cardiovascular screening, prevention, emergency management and return to sport. Materials and methods: A narrative review was conducted using PubMed, Web of Science and Google Scholar. English-language full-text studies published between 2015 and 2026 were considered, including original studies, systematic reviews, meta-analyses and narrative reviews. Results: SCD is uncommon, but its incidence varies between athlete populations and is higher in males. In younger athletes, cardiomyopathies, coronary artery anomalies and primary electrical disorders are important causes, while coronary artery disease becomes more relevant with age. ECG screening may improve the detection of cardiovascular conditions associated with SCD, although its effect on mortality remains uncertain. Early CPR and rapid AED use are consistently associated with better survival after sports-related cardiac arrest. Conclusions: Prevention should combine cardiovascular assessment with awareness of warning symptoms and effective emergency preparedness. Return-to-sport decisions should be individualized according to the underlying cardiovascular condition and follow-up findings.
- Open Access
- 29 April 2026
- Published by Springer Nature in Current Pharmacology Reports
- Vol. 12 (1) , 18
GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns
- 29 April 2026
- Published by Springer Nature in Current Pharmacology Reports
- Vol. 12 (1) , 18
Open AccessGLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns
- Open Access
- 5 December 2025
- Published by Springer Nature in Archives of Virology
- Vol. 171 (1) , 12
When serology misleads: cross-reactivity in acute hepatitis
Acute viral hepatitis (AVH) caused by hepatitis A virus (HAV), hepatitis E virus (HEV), Epstein-Barr virus (EBV), and cytomegalovirus (CMV) often presents with similar clinical and biochemical features. However, serological cross-reactivity among these viruses poses significant diagnostic challenges, potentially leading to misclassification, inappropriate management, and unreliable epidemiological data. To review the immunological mechanisms contributing to serological cross-reactivity in AVH and highlight the diagnostic and clinical implications, with a focus on the importance of molecular confirmation. A structured literature review was conducted using the PubMed, EMBASE, Scopus, and Web of Science databases. Keywords included terms related to cross-reactivity, acute hepatitis, serological testing, molecular diagnostics, and specific viral agents. Peer-reviewed studies published in English up to 2025 were included. Cross-reactivity in AVH is primarily driven by polyclonal B-cell activation, antibody polyreactivity, and T-cell receptor cross-specificity. Studies report that up to 33.3% of anti-HEV IgM–positive samples also test positive for EBV or CMV IgM, despite negative PCR confirmation. This overlap is particularly problematic in immunocompromised individuals and pregnant women, where accurate pathogen identification is critical. While PCR offers superior specificity and sensitivity, its implementation is limited by cost and accessibility in low-resource settings. Serological cross-reactivity in acute hepatitis significantly impacts diagnostic precision and clinical decision-making. Incorporating molecular testing, especially PCR, into diagnostic workflows is essential to ensure accurate diagnosis, particularly in high-risk populations.
- 5 December 2025
- Published by Springer Nature in Archives of Virology
- Vol. 171 (1) , 12
Open AccessWhen serology misleads: cross-reactivity in acute hepatitis
Acute viral hepatitis (AVH) caused by hepatitis A virus (HAV), hepatitis E virus (HEV), Epstein-Barr virus (EBV), and cytomegalovirus (CMV) often presents with similar clinical and biochemical features. However, serological cross-reactivity among these viruses poses significant diagnostic challenges, potentially leading to misclassification, inappropriate management, and unreliable epidemiological data. To review the immunological mechanisms contributing to serological cross-reactivity in AVH and highlight the diagnostic and clinical implications, with a focus on the importance of molecular confirmation. A structured literature review was conducted using the PubMed, EMBASE, Scopus, and Web of Science databases. Keywords included terms related to cross-reactivity, acute hepatitis, serological testing, molecular diagnostics, and specific viral agents. Peer-reviewed studies published in English up to 2025 were included. Cross-reactivity in AVH is primarily driven by polyclonal B-cell activation, antibody polyreactivity, and T-cell receptor cross-specificity. Studies report that up to 33.3% of anti-HEV IgM–positive samples also test positive for EBV or CMV IgM, despite negative PCR confirmation. This overlap is particularly problematic in immunocompromised individuals and pregnant women, where accurate pathogen identification is critical. While PCR offers superior specificity and sensitivity, its implementation is limited by cost and accessibility in low-resource settings. Serological cross-reactivity in acute hepatitis significantly impacts diagnostic precision and clinical decision-making. Incorporating molecular testing, especially PCR, into diagnostic workflows is essential to ensure accurate diagnosis, particularly in high-risk populations.
- 12 March 2025
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 59 (10) , 928-936
Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease
Objective: To summarize the current knowledge on the therapeutic potential of GLP-1 receptor agonists in managing metabolic associated steatotic liver disease (MASLD). Data Sources: A literature review was conducted using the search terms GLP-1 agonists , MASLD , NAFLD , nonalcoholic fatty liver disease , treatment , and therapy on PubMed (from January 1, 2019, through February 1, 2025), National Institutes of Health (NIH) (from January 1, 2019, through February 1, 2025), Scopus (from January 1, 2019, through February 1, 2025), and the World Health Organization (WHO) data. Study Selection and Data Extraction: All relevant clinical trials, review articles, package inserts, and guidelines evaluating clinically relevant evidence regarding the therapeutic potential of GLP-1 agonists in MASLD were considered for inclusion. Data Synthesis: GLP-1 RAs have shown promising results in MASLD treatment. Semaglutide has demonstrated efficacy in reducing liver fat content, inflammation, and fibrosis, with clinical trials indicating improvements in hepatic biomarkers and cardiometabolic risk factors. Similarly, tirzepatide has been associated with substantial weight loss and significant reductions in liver fat and fibrosis markers. Both agents exert their effects through mechanisms involving improved insulin sensitivity, reduced lipid accumulation, and attenuation of hepatic inflammation. Relevance to Patient Care and Clinical Practice: Given the high prevalence of MASLD in patients with obesity and type 2 diabetes, tirzepatide and semaglutide could play a critical role in clinical practice by addressing multiple facets of the disease. Both agents have shown potential in reducing liver fat, improving hepatic biomarkers, and mitigating cardiometabolic risks, which are leading causes of morbidity and mortality in MASLD patients. Incorporating these therapies into MASLD treatment guidelines could significantly enhance patient outcomes by targeting both liver-related and systemic complications of the disease. Conclusions: GLP1 RAs show great potential in managing MASLD by promoting weight loss, improving glycemic control, and reducing liver inflammation.
- 12 March 2025
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 59 (10) , 928-936
Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease
Objective: To summarize the current knowledge on the therapeutic potential of GLP-1 receptor agonists in managing metabolic associated steatotic liver disease (MASLD). Data Sources: A literature review was conducted using the search terms GLP-1 agonists , MASLD , NAFLD , nonalcoholic fatty liver disease , treatment , and therapy on PubMed (from January 1, 2019, through February 1, 2025), National Institutes of Health (NIH) (from January 1, 2019, through February 1, 2025), Scopus (from January 1, 2019, through February 1, 2025), and the World Health Organization (WHO) data. Study Selection and Data Extraction: All relevant clinical trials, review articles, package inserts, and guidelines evaluating clinically relevant evidence regarding the therapeutic potential of GLP-1 agonists in MASLD were considered for inclusion. Data Synthesis: GLP-1 RAs have shown promising results in MASLD treatment. Semaglutide has demonstrated efficacy in reducing liver fat content, inflammation, and fibrosis, with clinical trials indicating improvements in hepatic biomarkers and cardiometabolic risk factors. Similarly, tirzepatide has been associated with substantial weight loss and significant reductions in liver fat and fibrosis markers. Both agents exert their effects through mechanisms involving improved insulin sensitivity, reduced lipid accumulation, and attenuation of hepatic inflammation. Relevance to Patient Care and Clinical Practice: Given the high prevalence of MASLD in patients with obesity and type 2 diabetes, tirzepatide and semaglutide could play a critical role in clinical practice by addressing multiple facets of the disease. Both agents have shown potential in reducing liver fat, improving hepatic biomarkers, and mitigating cardiometabolic risks, which are leading causes of morbidity and mortality in MASLD patients. Incorporating these therapies into MASLD treatment guidelines could significantly enhance patient outcomes by targeting both liver-related and systemic complications of the disease. Conclusions: GLP1 RAs show great potential in managing MASLD by promoting weight loss, improving glycemic control, and reducing liver inflammation.